Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 402-408

  Yang, Jun ^a   Bohl, Casey E ^a   Nair, Vipin A ^b   Mustafa, Suni M ^b   Seoung, Soo Hong ^b   Miller, Duane D ^b   Dalton, James T ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c LM Parks Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; ESTROGEN; GLUCOCORTICOID RECEPTOR; IODINE DERIVATIVE; LIGAND; PROPIONAMIDE DERIVATIVE; S 3 (4 FLUOROPHENOXY) 2 HYDROXY 2 METHYL N (4 CYANO 3 IODOPHENYL) PROPIONAMIDE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; CYTOSOL; DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; TRANSACTIVATION;

AMIDES; ANIMALS; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MALE; NITRILES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645114469     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.094334     Document Type: Article

References (44)

1. Avvakumov GV, Grishkovskaya I, Muller YA, and Hammond GL (2002) Crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol reveals the molecular basis for high affinity interactions with C-2 derivatives of estradiol. J Biol Chem 277:45219-45225.
2. Berger B, Coffey DS, and Scott WW (1975) Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotopic scanning agents for the prostate. Investig Urol 13:10-16.
3. Bohl CE, Chang C, Mohler ML, Chen J, Miller DD, Swaan PW, and Dalton JT (2004) A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem 47:3765-3776.
4. Bohl CE, Gao W, Miller DD, Bell CE, and Dalton JT (2005a) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201-6206.
5. Bohl CE, Miller DD, Chen J, Bell CE, and Dalton JT (2005b) Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 280:37747-37754.
6. Bonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, Choe YS, Katzenellenbogen JA, and Welch MJ (1996) Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 37:1009-1015.
7. Bowman SP, Barnes DM, Blacklock NJ, and Sullivan PJ (1986) Regional variation of cytosol androgen receptors throughout the diseased human prostate gland. Prostate 8:167-180.
8. Brandes SJ and Katzenellenbogen JA (1987) Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol Pharmacol 32:391-403.
9. Brolin J, Lowhagen T, and Skoog L (1992) Immunocytochemical detection of the androgen receptor in fine needle aspirates from benign and malignant human prostate. Cytopathology 3:351-357.
10. Carlson KE and Katzenellenbogen JA (1990) A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat. J Steroid Biochem 36:549-561.
11. Choe YS, Lidstrom PJ, Chi DY, Bonasera TA, Welch MJ, and Katzenellenbogen JA (1995) Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorinationreduction, receptor binding and tissue distribution. J Med Chem 38:816-825.
12. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD (1998) Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4.
13. Frydenberg M, Foo TM, Jones AS, Grace J, Hensley WJ, Rogers J, Pearson BS, and Raghavan D (1991) Benign prostatic hyperplasia-video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol 146:872-876.
14. Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S, and Shikama H (2002) Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun 294:779-784.
15. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, and Dalton JT (2005) Selective androgen receptor modulator (SARM) treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146:4887-4897.
16. Greenlee RT, Hill-Harmon MB, Murray T, and Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15-36 [erratum appears in CA Cancer J Clin (2001 Mar-Apr) 51:144].
17. Habib FK, Odoma S, Busuttil A, and Chisholm GD (1986) Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor. Cancer 57:2351-2356.
18. He Y, Yin D, Perera M, Kirkovsky L, Stourman N, Li W, Dalton JT, and Miller DD (2002) Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem 37:619-634.
19. Kavoussi LR, Sosa E, Chandhoke P, Chodak G, Clayman RV, Hadley HR, Loughlin KR, Ruckle HC, Rukstalis D, and Schuessler W (1993) Complications of laparoscopic pelvic lymph node dissection. J Urol 149:322-325.
20. Kearbey JD, Wu D, Gao W, Miller DD, and Dalton JT (2004) Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3- trifluoromethylphenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 34:273-280.
21. Kim J, Wu D, Hwang DJ, Miller DD, and Dalton JT (2005) The 4-para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl- phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 315:230-239.
22. Kirkovsky L, Mukherjee A, Yin D, Dalton JT, and Miller DD (2000) Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J Med Chem 43:581-590.
23. Labaree DC, Hoyte RM, Nazareth LV, Weigel NL, and Hochberg RB (1999) 7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents. J Med Chem 42:2021-2034.
24. Liu A, Carlson KE, and Katzenellenbogen JA (1992) Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 35:2113-2129.
25. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, and Miller DD (2004) Design, synthesis and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem 47:993-998.
26. Mukherjee A, Kirkovsky LI, Kimura Y, Marvel MM, Miller DD, and Dalton JT (1999) Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol 58:1259-1267.
27. Nair VA, Mustafa SM, Mohler ML, Fisher SJ, Dalton JT, and Miller DD (2004) Synthesis of novel iodo derived bicalutamide analogs. Tetrahedron Lett 45:9475-9477.
28. Nair VA, Mustafa SM, Mohler ML, Yang J, Dalton JT, and Miller DD (2005) Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Lett 46:4821-4823.
29. Neal CE and Meis LC (1994) Correlative imaging with monoclonal antibodies in colorectal, ovarian and prostate cancer. Semin Nucl Med 24:272-285.
30. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR Jr, et al. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904-4909.
31. Sadi MV, Walsh PC, and Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064.
32. Salman M and Chamness GC (1991) A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2′-(E)-iodovinyl)-19- nortestosterone. J Med Chem 34:1019-1024.
33. Shain SA, Gorelic LS, Klipper RW, Ramzy I, Novicki DE, Radwin HM, and Lamm DL (1983) Inability of cytoplasmic or nuclear androgen receptor content or distribution to distinguish benign from carcinomatous human prostate. Cancer Res 43:3691-3695.
34. Symes EK (1982) Uptake and retention of androgens by the rat ventral prostate and consideration of their use as site directing agents. Biochem Pharmacol 31:3231-3236.
35. Takeda H, Chodak G, Mutchnik S, Nakamoto T, and Chang C (1990) Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. J Endocrinol 126:17-25.
36. Tucker H, Crook JW, and Chesterson GJ (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J Med Chem 31:954-959.
37. Tveter KJ and Attramadal A (1968) Selective uptake of radioactivity in rat ventral prostate following administration of testosterone-1,2-3H. Methodological considerations. Acta Endocrinol (Copenh) 59:218-226.
38. van Aubel OG, Bolt-de Vries J, Blankenstein MA, ten Kate FJ, and Schroder FH (1985) Nuclear androgen receptor content in biopsy specimens from histologically normal, hyperplastic and cancerous human prostatic tissue. Prostate 6:185-194.
39. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, and Trapman J (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193.
40. Van der Kwast TH, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, and Labrie F (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate 28:227-231.
41. Waller AS, Sharrard RM, Berthon P, and Maitland NJ (2000) Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. J Mol Endocrinol 24:339-351.
42. Winneker RC, Wagner MM, and Singh B (1990) A novel, nonsteroidal inhibitor of androgen binding to the rat androgen binding protein: diethyl [[[3-(2,6-dimethyl-4-pyridinyl)-4-fluorophenyl]amino]methylene] propanedioate. J Med Chem 33:129-132.
43. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, and Dalton JT (2003a) Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 304:1334-1340.
44. Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, and Dalton JT (2003b) Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 63:211-223.